NewslettersImmune Regulation NewsAfter Oncology Wind-Down, TG’s Pivot to MS Faces Setback as FDA Pushes Approval DecisionBy Danielle Corrigan - May 31, 20220351After winding down its oncology program to pivot to multiple sclerosis (MS), TG Therapeutics has suffered a fresh setback as its lead candidate faces an additional three-month wait for an FDA decision.[Fierce Biotech]Press Release